Resources

Information for applicants who intend to apply for a medicinal cannabis permit for medicinal or scientific purposes – cultivation and production activities.

Information for applicants who intend to apply for a medicinal cannabis permit for medicinal or scientific purposes – manufacture activities.

The Therapeutic Goods Order No. 93 (Standard for Medicinal Cannabis) ensures that medicinal cannabis products meet quality standards, whether or not those products are imported or manufactured domestically. 

The Office of Drug Control Business Plan for January-June 2022 is now available.

The Narcotic Drugs Act 1967 gives effect to some of Australia’s obligations under the Single Convention on Narcotic Drugs, 1961.

The Narcotic Drugs (Licence Charges) Regulation 2016 puts into place the regulatory licence charges for licences relating to medicinal cannabis, commercial cannabis research and non-commercial cannabis research as provided for under the Narcotic Drugs (Licence Charges) Act 2016.

Information on how the Office of Drug Control implements cost recovery for regulatory activities.

Information on how the Office of Drug Control implements cost recovery for regulatory activities.

Guidance for completing an application for a new licence to cultivate, produce and/or manufacture medicinal cannabis or cannabis material.

Webinar slides from the Medicinal cannabis reform single licence reform information session held on 13 October 2021.

Guidance note for 'Testing of cannabis and cannabis resin' updated.

The Narcotic Drugs Amendment (Medicinal Cannabis) Regulations 2021 introduced a requirement for a review of the medicinal cannabis scheme to be undertaken.

Response to the report on the inquiry into the RMC Bill

The Australian Government response to the Inquiry into current barriers to patient access to medicinal cannabis has now been published.

On 11 October 2019, the Prime Minister, the Hon Scott Morrison MP, announced that the Australian Government is stepping up its commitment to the Pacific by launching the kava pilot program (pilot). The pilot involves the relaxation of kava related prohibited import regulations to allow Australians more access to kava and its benefits.

Presentation slides from the Kava pilot phase 2 design webinar on 4 November 2020.

Guideline to assist licence applicants and holders in designing and meeting security standards that are required for the cultivation, production and manufacture of medicinal cannabis.

Information on how the Office of Drug Control implements cost recovery for regulatory activities associated with the direct costs of processing licence and permit applications for the cultivation of medicinal cannabis and the ongoing monitoring and compliance of the regulatory scheme.

This form authorises the Office of Drug Control (Department of Health and Aged Care) to obtain information on an individual named in an application for the grant or variation of a licence under the Narcotic Drugs Act 1967.

A comprehensive review of the Medicinal Cannabis Cost Recovery Framework was undertaken in
late 2019 and early 2020. This paper presents the findings of that review.

The Government is inviting feedback on the proposal to implement a single medicinal cannabis licence under the Narcotic Drugs Act 1967 and other associated reforms to the licence application process.

Our plan for how HPRG will maintain and build its regulatory science capability over the next 5 years.

Example follow-up questions to assist applicants in preparing their medicinal cannabis licence applications.

Guideline to assist licence applicants and holders to assess whether they are fit and proper to hold a licence to cultivate, produce or manufacture medicinal cannabis and products.

Guideline to assist licence applicants and holders in designing and meeting standards required for record keeping and reporting matters related to cultivation, production and manufacture of medicinal cannabis.